This published case report memorializes the success of cannabis extract for acute lymphoblastic leukemia (ALL) . There are thousands of published “spontaneous remissions” and anecdotal reports confirming the efficiency of holistic cancer treatments, including cannabis therapy. But few of these cases have been published in the peer-reviewed medical literature. And for those cases that have been diligently monitored in a hospital setting, there are even fewer cases. It therefore makes pedagogical sense to examine in detail this case.
SUMMARY OF THE FACTS
After 34-months of chemo, radiation and bone marrow transplant treatments, a 14 year old girl, initialed P.K., was declared terminal. Her acute lymphoblastic leukemia (ALL) was diagnosed as a very aggressive one (i.e. conventional treatment resistant). (1) Thereafter, she took hemp oil for 78 days, at which point all of her ALL leukemia cells were put in remission, from over 300,000 blast cells, cannabis brought it down to 0,3.
THE DETAILED FACTUAL CIRCUMSTANCES
P.K. presented symptoms of weakness, shortness of breath and bruising when she was taken to the Hospital for Sick Children, Toronto, Canada, on or around the 10th March 2006. She was diagnosed with acute lymphoblastic leukemia (ALL), with over 300,000 blast cells present.
Acute chemotherapy followed by a standard chemotherapy regimen went on for 6 months after the diagnosis. Upon further analysis, she was found to be positive for the Philadelphia chromosome mutation. (ie a mutation in the Philadelphia chromosome is a much more aggressive form of ALL). When standard treatment options were unsuccessful, a bone marrow transplant was pursued. She successfully received the transplant in August 2006 and was able to be released from isolation 45 days later. She was observed posttransplant by following the presence of blast cells, noted 6 months after treatment. Consequently, in February 2007, aggressive chemotherapy procedures were administered along with a tyrosine kinase inhibitor, imatinib mesylate (Gleevac), 500 mg orally twice a day. In November 2007, 9 months after the transplant, the presence of premature blast cells was observed and it was determined that another bone marrow transplant would not be effective. In February 2008, in an effort to sustain the patient, another tyrosine kinase inhibitor, disatinib (Sprycel), was administered at 78 mg twice a day with no additional rounds of chemotherapy. The patient experienced increased migraine-like headaches in June 2008. After conducting a CT scan of the head in July 2008, cerebellitis was noted. It was assumed by the primary oncologist that the blast cells could have infiltrated the CNS and be present in the brain, although none were noted in the blood. By October 2008, ten treatments of radiation therapy had been administered to the brain. Thereafter, on the 4th February 2009, blood was noted in the patient’s stools and a blood cell count revealed the presence of blast cells. As a result, all treatment including the disatinib was suspended and the patient’s medical staff acknowledged failure in treating her cancer. (2) (Cf also EXHIBIT C)
At the Canadian hospital, the hematologists-oncologists charted the patient’s treatment failure as follows, in pertinent part:
“…suffers from terminal malignant disease. She has been treated to the limits of available therapy… no further active intervention will be undertaken’. She was placed in palliative home care and told to prepare for her disease to overwhelm her body and from which she would suffer a stroke within the next 2 months”. (Source)
After this terminal verdict, disease progression was observed with rising counts of blast cells. The patient received frequent blood transfusions and platelets during this period. From the 4th to the 20th of February, the patient’s blast cell count had risen from 51,490 to 194,000.
As a last recourse, the parents decided to resort to holistic medicine, in particular to cannabis therapy. The first dose of cannabinoid medicine, was administered orally at 6:30 a.m. on the 21st February 2009 (ie, day 0, see EXHIBIT A, below). At this stage of her disease, the blast cell count was over 300,000.
After 78 days, the leukemia went away, was put in remission. From over 300,000 white blood cells, the cannabis brought these down to 0.3. But in actuality, it only took about one month for the curve to significantly change (EXHIBIT B, below)
IMPROVEMENT, THEN DEATH
After this spectacular improvement, the patient nonetheless died. The facts show that the little girl passed away less because of the cannabis than because of the chemo-radiation that she was previously administered. (3)
As reported by Hematology/Oncology at SickKids:
“At admission her total WBC was 1.4, hemoglobin was 82, platelet count 8,000. She was profoundly neutropenic… a prior history of pancolitis documented by CT scan in March 2009 was neutropenic colitis with perforation… her abdomen was distended and obviously had some signs of diffuse peritonitis. The abdomen X-ray was in favour a perforation…she passed away at 10:05 in the present (sic) of family”.(Source)
From analyzing the evidence, this little girl’s remission cannot be attributed to the phenomenon of ‘spontaneous remission’ nor delayed conventional care because a cannabis dose response curve was achieved. (4) P.K was under palliative care and was solely on cannabinoid treatment when the response was documented by the SickKids Hospital. The toxicology reports ruled out chemotherapeutic agents, and only showed her to be positive for THC (tetrahydrocannabinol) when she had the massive decrease of WBC from 350,000 to 0.3. (Source)
This case suggests that the safety profile and the efficiency of cannabis are empirically established by an overwhelming preponderance of the evidence, thanks to hospital charts and diligent monitoring. Where allopathic oncology had failed to control the blast cell counts and had devastating side effects that ultimately resulted in the death of the patient, the holistic cannabinoid therapy was efficient in reducing the white blood cell count, (5) in increasing the patient’s wellbeing and vitality and in doing this without recorded toxic side effects. (6)
Top: Picture of the cannabis female bud, rich in cannabinoid resin
PRECISION AND REFERENCE NOTES
(1) These liquid cancers tend to be positive for the Philadelphia chromosome mutation.
(2). Case Rep Oncol. 2013 Nov 28;6(3):585-92.
(3). In addition, if her oncologists did not support her liver and kidneys, inter alia, tumor lysis (syndrome) may have factored in the death as rapid cancer die-off can induce serious complications. Furthermore, there is a strong presumption that the cannabis the patient took mitigated some of the ill effects of chemo-radiation as this is often the case, including, but not limited to heart attacks (Source). But in P.K’s case, the conventional treatment was just too devastating for her to survive it.
(4). Curves like these are usually the result of dosing frequency, amount (therapeutic dosing) and the potency of the molecule, in this case the cannabis strain. All of these factors were critical in determining response and disease control.
(5). In the beginning of the cannabis therapy, the patient did feel nauseated with fatigue. But this may have been the result of both the after effects of chemo-radiation and because she may have not been used to high concentrations of hemp oil. The major “side effects” charted were psychosomatic in nature, euphoric, with an increased appetite.
(6). There are many mechanisms of action which have been identified in advanced cannabis research, including, but not limited to those that modulate signaling pathways, from apoptotic and angiogenic to metastatic, inter alia. Cf. Powles T, Poele RT, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, Liu WM. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood. 2005;105:1214–1221.
Case Rep Oncol. 2013 Nov 28;6(3):585-92.
Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation.
Singh Y1, Bali C2.
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells and is typically well treated with combination chemotherapy, with a remission state after 5 years of 94% in children and 30-40% in adults. To establish how aggressive the disease is, further chromosome testing is required to determine whether the cancer is myeloblastic and involves neutrophils, eosinophils or basophils, or lymphoblastic involving B or T lymphocytes. This case study is on a 14-year-old patient diagnosed with a very aggressive form of ALL (positive for the Philadelphia chromosome mutation). A standard bone marrow transplant, aggressive chemotherapy and radiation therapy were revoked, with treatment being deemed a failure after 34 months. Without any other solutions provided by conventional approaches aside from palliation, the family administered cannabinoid extracts orally to the patient. Cannabinoid resin extract is used as an effective treatment for ALL with a positive Philadelphia chromosome mutation and indications of dose-dependent disease control. The clinical observation in this study revealed a rapid dose-dependent correlation.
Copyright (c) 2015: ACRI and agents.
Advanced Cancer Research Institute’s Director, Christian Joubert, has contributed in the coming and edification of a needed spiritual civilization by working as a professor of international public law in France and at Gonzaga Law School as well as in holistic medicine and other disciplines in different universities and institutes for most of his adult life. In association with his activities in clinical practice, organic agriculture, eco-development, community building, he has also actively participated via litigation and education in the legal protection of internationally recognized human rights, focusing on the protection of fundamental health rights and medical freedoms. He is presently working on a documentary and a book on Holistic Oncology, both of which have been designed to promote the necessary paradigm shift that will forever replace today's outdated, dogmatic, ideological and bankrupted conventional oncology model with progressive, evidence-based, sustainable and resilient holistic standards of care that are much more efficient, safe and cost-friendly than what persists in today's mainstream. See link on mission for more details.